Is there data to support the substitution of docetaxel with nab-paclitaxel in the TCHP neoadjuvant regimen in the event of hypersensitivity?

I am not aware of extensive data. I do see a couple of case reports: Pellegrino et al., PMID 29083340. There is a nice summary of chemotherapy for HER2 disease provided by ASCO published recently, "Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer...